Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Acquires $11,999,991.20 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III bought 1,034,482 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the acquisition, the insider now directly owns 795,411 shares in the company, valued at approximately $9,226,767.60. This trade represents a -432.71 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Surrozen Stock Performance

Shares of Surrozen stock opened at $11.01 on Monday. Surrozen, Inc. has a 1-year low of $6.00 and a 1-year high of $18.17. The business has a 50-day moving average of $11.37 and a 200-day moving average of $10.98.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright started coverage on shares of Surrozen in a report on Thursday, January 30th. They set a “buy” rating and a $32.00 target price on the stock. Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, January 3rd.

Institutional Investors Weigh In On Surrozen

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after purchasing an additional 4,630 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in shares of Surrozen in the fourth quarter worth $688,000. Adage Capital Partners GP L.L.C. acquired a new stake in Surrozen in the fourth quarter valued at $928,000. Regents of The University of California bought a new position in Surrozen during the 4th quarter valued at $1,912,000. Finally, Stonepine Capital Management LLC grew its holdings in Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after acquiring an additional 27,200 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.